SC
AUPH icon

Sculptor Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Sculptor Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-189,900
Closed -$1.19M – 321
2017
Q3 		$1.19M Sell
189,900
-4,800
-2% -$30.3K 0.01% 244
2017
Q2 		$1.19M Buy
+194,700
New +$1.31M 0.01% 244

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Sculptor Capital's AUPH Position: Q1 2018 in Review

Sculptor Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2018, closing a stake of 127,200 shares — an estimated $576K sold.

Sculptor Capital first reported a position in AUPH in Q2 2017 and held it in 3 quarters. The position peaked at $1.16M in Q2 2017. 64 funds tracked by Wall St. Rank hold AUPH as of Q1 2018.

  • Sculptor Capital reported no remaining Aurinia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Sculptor Capital sold 127,200 Aurinia Pharmaceuticals shares in Q1 2018, an estimated $576K.
  • Sculptor Capital first reported a position in Aurinia Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Sculptor Capital's Aurinia Pharmaceuticals position peaked at $1.16M in Q2 2017.
  • 64 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2018.

Based on Sculptor Capital's 13F filing for Q1 2018, filed 14 May 2018.